Goodness Growth Holdings Signs Definitive Agreement to Acquire Charm City Medicus Dispensary in Baltimore, Maryland

Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a physician-led, science-focused cannabis company and IP developer, today announced that its subsidiary, Vireo of Charm City, LLC, has signed a definitive agreement to purchase all substantial assets of Charm City Medicus, LLC, a medical cannabis dispensary located in Baltimore, Maryland .

"We are very pleased to be expanding our retail market share in Maryland's medical cannabis market and look forward to introducing our Green Goods™ dispensary brand to the Baltimore area," said Chairman and Chief Executive Officer, Kyle Kingsley , M.D. "With our recent initiatives to expand cultivation and processing capacity in Maryland , we're in an excellent position to continue growing our wholesale and retail sales in the state as our manufacturing capabilities enable us to offer the full spectrum of cannabis products to patients. We also plan to leverage this new location to support engagement activities in the local community through our expungement clinics and other social events."

The Company expects the transaction to close later this year, pending approval of the dispensary license transfer by the Maryland Medical Cannabis Commission. The Company expects total consideration for the transaction at closing of US $8.0 million , including $4.0 million in cash, $2.0 million in Goodness Growth stock, and a $2.0 million promissory note issued to the seller. Goodness Growth shares issued in conjunction with the transaction will be subject to a one-year lock-up agreement. Upon closing of the transaction, the Company expects to transition Charm City to the Green Goods™ brand of retail dispensaries.

About Goodness Growth Holdings, Inc.

Goodness Growth Holdings, Inc., is a physician-led, science-focused holding company whose mission is to bring the power of plants to the world. The Company's operations consist primarily of its multi-state cannabis company subsidiary, Vireo Health, and its science and intellectual property developer, Resurgent Biosciences. The Company manufactures proprietary, branded cannabis products in environmentally friendly facilities and state-of-the-art cultivation sites and distributes its products through its growing network of Green Goods™ and other retail locations and third-party dispensaries. Its teams of more than 500 employees are focused on the development of differentiated products, driving scientific innovation of plant-based medicines, and developing meaningful intellectual property. Today, the Company is licensed to grow, process, and/or distribute cannabis in eight markets and operates 17 dispensaries across the United States . For more information about Goodness Growth Holdings, please visit www.goodnessgrowth.com .

Contact Information

Investor Inquiries :

Media Inquiries :

Sam Gibbons

Albe Zakes

Vice President, Investor Relations

Vice President, Corporate Communications

samgibbons@vireohealth.com

albezakes@vireohealth.com

(612) 314-8995

(267) 221-4800

Forward-Looking Statement Disclosure

This press release contains "forward-looking information" within the meaning of applicable United States and Canadian securities legislation. To the extent any forward-looking information in this press release constitutes "financial outlooks" within the meaning of applicable United States or Canadian securities laws, such information is being provided as preliminary financial results and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking information contained in this press release may be identified by the use of words such as "plan," "position," "continue," "will," "expects," "pending,"or variations of such words and phrases.  These statements should not be read as guarantees of future performance or results. Forward-looking information includes both known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company or its subsidiaries to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements or information contained in this press release. Forward-looking information is based upon a number of estimates and assumptions of management, believed but not certain to be reasonable, in light of management's experience and perception of trends, current conditions, and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, risks related to current and future economic conditions; risks related to the COVID-19 pandemic; federal, state, local, and foreign government laws, rules, and regulations, including federal and state laws in the United States relating to psychedelics  and any changes to such laws; operational, regulatory, and other risks; execution of business strategy; difficulty to forecast; conflicts of interest; liquidity and additional financing; and risk factors set out in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 , which is available on EDGAR with the U.S. Securities and Exchange Commission and filed with the Canadian securities regulators and available under the Company's profile on SEDAR at www.sedar.com .

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results, or otherwise, other than as required by applicable securities laws.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/goodness-growth-holdings-signs-definitive-agreement-to-acquire-charm-city-medicus-dispensary-in-baltimore-maryland-301328496.html

SOURCE Goodness Growth Holdings

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Cannabis leaf.

10 Biggest Cannabis Stocks in the US and Canada in 2026

After a year of stop‑start policy signals, the US cannabis market ended 2025 with a new wave of attention as US President Donald Trump moved to accelerate federal cannabis rescheduling efforts. His December executive order directing the attorney general to complete the process of shifting... Keep Reading...
Cannabis business with marijuana leaves and stock

Cannabis Market 2025 Year-End Review

2025 marked a turning point for investment in the cannabis sector, shifting the focus toward operational resilience and consolidation after a sluggish 2024. Key market drivers included an upswing in merger and acquisition (M&A) activity as stronger multi-state operators (MSOs) acquired... Keep Reading...
Cannabis plant with green leaves and buds on a dark green background.

Cannabis Market Forecast: Top Trends for Cannabis in 2026

The US cannabis market is entering 2026 with brighter prospects after a punishing few years marked by stalled rescheduling efforts, price compression, retail saturation and slow state expansion.Now, however, regulatory tailwinds seeming aligned for a potential re-rating.On December 18, US... Keep Reading...
Cannabis plant in focus, blurred US flag background.

Analysts React: Trump Signs Executive Order to Reschedule Cannabis

The long-debated issue of US cannabis rescheduling is finally back in the spotlight. On Thursday (December 18), President Donald Trump signed an executive order to expedite the process of moving cannabis from Schedule I to Schedule III under the Controlled Substances Act. Market watchers are now... Keep Reading...
Close-up of green cannabis leaves in natural light.

Trump Weighs Executive Order to Loosen Federal Cannabis Restrictions

US President Donald Trump is reportedly weighing a major shift in federal drug policy that would relax decades-old restrictions on cannabis, potentially injecting new life into the industry. Six people familiar with the discussions told the Washington Post that Trump is preparing an executive... Keep Reading...
Gavel on a surface with scattered cannabis leaves, symbolizing legal issues around marijuana.

Hemp THC Recriminalization: A Blow to a Blooming Industry

A spending bill to reopen the US government after a 43 day shutdown includes provisions that will recriminalize most hemp-derived THC products. This change, slated to become effective one year after enactment, in late 2026, marks a significant policy reversal from the 2018 Farm Bill, which... Keep Reading...

Interactive Chart

Latest Press Releases

Related News